Marsons Ltd
MARSONSMarsons Ltd's earnings have outrun its stock. EPS grew +65.0% in a year against a −43.3% price move.
The sharpest disagreement: profits are rising, but only −49% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a downtrend (41 weeks in) while the P/E sits at the 31st percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +155.6% year on year, and −49% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Marsons Ltd trades at ₹110, in a downtrend and 41 weeks into that stage. That is −22.6% against its own 200-day average. It sits at 0% of a 52-week range of ₹110 to ₹184. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (15 weeks and counting).
Today the stock is in a downtrend — week 41 of stage 4, confirmed. At ₹110 it trades −22.6% versus its 200-day average and sits at 0% of its 52-week range (₹110–₹184).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +845% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (15 weeks and counting; last ahead the week of 2026-05-29) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Marsons Ltd trades at 40.9× P/E, near the bottom of its own range — cheaper only 31% of the time. Its long-run median P/E is 71.6×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 40.9× is near the bottom of its own range — cheaper only 31% of the time, against a long-run median of 71.6× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +65.0% against a −43.3% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 10y, of the +22.9%/yr price move, ~+5.3%/yr came from earnings growth and ~+17.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Marsons Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +2579.2% at its peak to +45.6% but is still expanding, ROCE holding at 25.0%. The read is built from 11 quarters across 4 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +45.8% | +265.9% | — | +9.1% |
| Profit | +64.3% | +148.4% | — | +27.7% |
| EPS | +65.0% | +117.9% | — | +4.9% |
| Share price | −43.3% | +175.0% | +61.9% | +22.9% |
4-Factor Sector Score
58.5/100 — rank 2 of 12 in Capital Goods - Transformers · 77% evidence confidence
Marsons Ltd scores 58.5 out of 100 against the 12 companies it is compared with in Capital Goods - Transformers, ranking 2. Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.5% and the one-year return is -43.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
The four contributions add to the total exactly: 26.3 + 15.4 + 12.2 + 4.6 = 58.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Marsons Ltd reported ₹93.0 Cr of revenue in the Mar 26 quarter, +66.1% year on year. That is the 9th straight quarter of year-on-year growth. Over 10 years it has compounded at 9.1% a year. The last full year, FY26, came in at ₹245 Cr. The last four reported quarters add to ₹246 Cr.
FY26 revenue came in at ₹245 Cr (+45.8% on the year), capping 10 years at 9.1% compound. The latest quarter (Mar 26) printed ₹93.0 Cr, +66.1% year on year — the 9th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +45.3% growth against the decade's 9.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +45.6% over the last 4 quarters against +491.5%/yr over the last 8 — rolling over; TTM profit +70.4% vs +4,695.8%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Marsons Ltd's operating margin is 21.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. Across 14 fiscal years the operating margin has ranged −5,506.0% to 23.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 21.0%, +3.0 pp against the same quarter a year ago. Across 14 fiscal years the operating margin has ranged −5,506.0%–23.0%.
Why the margin moved: operating margin went +2.4 pp year on year while gross margin went −3.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Marsons Ltd earned ₹23.0 Cr of net profit in the Mar 26 quarter, +155.6% year on year. Full-year FY26 profit was ₹46.0 Cr. The 10-year compound rate is 27.7%. That is 24.7% of the quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹23.0 Cr, +155.6% year on year. On the full year, FY26 printed ₹46.0 Cr (+64.3%), and the 10-year compound rate is 27.7%.
Why profit moved: revenue contributed +66.1% and the margin +3.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +61.0% vs revenue +45.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years −49% of Marsons Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹2.0 Cr of operating cash against ₹46.0 Cr of profit. After ₹77.0 Cr of capital spending, ₹−75.0 Cr was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY26: operating cash of ₹2.0 Cr against reported profit of ₹46.0 Cr, leaving free cash of ₹−75.0 Cr after ₹77.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −49% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −49%: the cash cycle tightened 7,701 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: the bigger cash user is investment — capital spending ran 39.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Marsons Ltd's cash conversion cycle runs 163 days in FY26, down from 7,864 days in FY21. Capital spending ran ₹79.0 Cr over the last 3 years. At FY26 sales of ₹245 Cr each day of that cycle holds about ₹0.7 Cr, so roughly ₹109 Cr sits inside the business at any moment.
FY26: debtors at 160 days, inventory at 111 days — roughly 3.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 163 days, tighter than FY21's 7,864.
The full loop: cash goes out to suppliers and production on day 0; stock waits 111 days to sell; customers pay about 160 days after that; and suppliers themselves are paid at 107 days — netting out to the 163-day cycle.
In money terms: at FY26 sales of ₹245 Cr, each day of the cycle holds about ₹0.7 Cr — so the 163-day loop keeps roughly ₹109 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹79.0 Cr over the last 3 fiscal years against ₹2.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹25.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Marsons Ltd earns a ROCE of 25% in FY26. That is up from a trough of −101% in FY18. Return on invested capital clears the cost of that capital by +11.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 18.8% net margin on 0.84× asset turns.
FY26 ROCE is 25%, recovered from a FY18 trough of −101% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 18.8% net margin × 0.84× asset turns × 1.34× balance-sheet leverage ≈ 21.2% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 23.9% − 12.0% = a +11.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Marsons Ltd carries total debt of ₹1.0 Cr against shareholder equity of ₹218 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹1.0 Cr against shareholder equity of ₹218 Cr — a debt-to-equity of 0.00. The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Marsons Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved +0.1 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +0.2 points over 8 quarters to 0.2%; Foreign institutions: +0.1 points over 8 quarters to 0.1%; Promoters: +0.0 points over 8 quarters to 53.6%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Marsons Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Indo Tech Transformers LtdINDOTECH | 84.8/100Sector-leading setup96% evidence | LEADER | 30.9/35 Revenue 28% · PAT 45.3% · OPM change 4 pp 88% evidence | 21.1/25 ROCE 37.7% · OPM 14% 100% evidence | 12.8/20 P/E 39.5× · PEG 0.45 100% evidence | 20.0/20 RS sector 59.7% · RS bench 74.2% · 1Y 86.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.9 + 21.1 + 12.8 + 20 = 84.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Marsons Ltdthis pageMARSONS | 58.5/100Mixed-positive evidence77% evidence | ASLEEP | 26.3/35 Revenue 45.6% · PAT 70.4% · OPM change 3 pp 83% evidence | 15.4/25 ROCE 25.4% · OPM 21% 95% evidence | 12.2/20 P/E 40.9× · PEG — 50% evidence | 4.6/20 RS sector -14.5% · RS bench -28.4% · 1Y -43.5%2 of 11 weeks ahead 70% evidence |
| Exact sum: 26.3 + 15.4 + 12.2 + 4.6 = 58.5 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.5% and the one-year return is -43.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Supreme Power Equipment LtdSUPREMEPWR | 53.2/100Mixed-positive evidence83% evidence | FADING | 20.0/35 Revenue 22.5% · PAT 12.7% · OPM change 0 pp 83% evidence | 15.9/25 ROCE 22% · OPM 18% 95% evidence | 12.3/20 P/E 25.4× · PEG — 50% evidence | 5.0/20 RS sector -8.7% · RS bench 1.4% · 1Y 1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 15.9 + 12.3 + 5 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4CG Power & Industrial Solutions LtdCGPOWER | 51.8/100Mixed-positive evidence100% evidence | FADING | 18.7/35 Revenue 21.4% · PAT 24% · OPM change -1 pp 100% evidence | 16.1/25 ROCE 26.7% · OPM 12% 100% evidence | 1.5/20 P/E 107× · PEG 5.21 100% evidence | 15.5/20 RS sector 2% · RS bench 13.1% · 1Y 30.3%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 16.1 + 1.5 + 15.5 = 51.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shilchar Technologies LtdSHILCTECH | 50.0/100Mixed-positive evidence78% evidence | ASLEEP | 9.1/35 Revenue 4.5% · PAT 6.8% · OPM change -10 pp 83% evidence | 21.1/25 ROCE 50.7% · OPM 21% 76% evidence | 9.7/20 P/E 33.1× · PEG — 50% evidence | 10.1/20 RS sector -4.4% · RS bench 6.6% · 1Y -6.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 9.1 + 21.1 + 9.7 + 10.1 = 50 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Schneider Electric Infrastructure LtdSCHNEIDER | 47.4/100Mixed-negative evidence96% evidence | LEADER | 7.5/35 Revenue 9.6% · PAT -20.9% · OPM change -7 pp 88% evidence | 16.3/25 ROCE 29.6% · OPM 8% 100% evidence | 6.1/20 P/E 145× · PEG 2.79 100% evidence | 17.5/20 RS sector 26.4% · RS bench 38.7% · 1Y 48.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 7.5 + 16.3 + 6.1 + 17.5 = 47.4 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7Transformers & Rectifiers India LtdTARIL | 43.6/100Mixed-negative evidence75% evidence | ASLEEP | 14.1/35 Revenue 14.7% · PAT 2.3% · OPM change -1 pp 95% evidence | 14.1/25 ROCE 23.3% · OPM 16% 76% evidence | 9.9/20 P/E 34.4× · PEG — 15% evidence | 5.5/20 RS sector -24.9% · RS bench -16.3% · 1Y -39.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 14.1 + 9.9 + 5.5 = 43.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Voltamp Transformers LtdVOLTAMP | 43.5/100Mixed-negative evidence100% evidence | ASLEEP | 14.1/35 Revenue 17.8% · PAT -2.8% · OPM change -2 pp 100% evidence | 14.5/25 ROCE 23.5% · OPM 15% 100% evidence | 3.1/20 P/E 31.7× · PEG 4.92 100% evidence | 11.8/20 RS sector 3.1% · RS bench 14.8% · 1Y 12.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 14.5 + 3.1 + 11.8 = 43.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Ujaas Energy LtdUEL | 34.6/100Adverse evidence74% evidence | ASLEEP | 8.9/35 Revenue -26.9% · PAT -47.7% · OPM change 30.2 pp 95% evidence | 2.4/25 ROCE 3.9% · OPM -92.1% 95% evidence | 8.5/20 P/E 522× · PEG — 15% evidence | 14.8/20 RS sector 14.6% · RS bench 10.3% · 1Y 73%0 of 10 weeks ahead 70% evidence |
| Exact sum: 8.9 + 2.4 + 8.5 + 14.8 = 34.6 · Decision use: Price leads the evidence: RS versus the benchmark is 10.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Bharat Bijlee LtdBBL | 31.3/100Adverse evidence96% evidence | ASLEEP | 15.8/35 Revenue 19.5% · PAT -10.4% · OPM change -3 pp 88% evidence | 4.4/25 ROCE 8.4% · OPM 7% 100% evidence | 8.6/20 P/E 23.8× · PEG 4.48 100% evidence | 2.5/20 RS sector -20.3% · RS bench -10.5% · 1Y -14.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 4.4 + 8.6 + 2.5 = 31.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Danish Power LtdDANISH | 50.5/100Thin evidence · provisional50% evidence | ASLEEP | 16.0/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 16.4/25 ROCE 23.4% · OPM 18% 95% evidence | 11.2/20 P/E 23.2× · PEG — 15% evidence | 6.9/20 RS sector -20.2% · RS bench 2.6% · 1Y -15.9%8 of 10 weeks ahead 70% evidence |
| Exact sum: 16 + 16.4 + 11.2 + 6.9 = 50.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Vilas Transcore LtdVILAS | 43.3/100Thin evidence · provisional50% evidence | ASLEEP | 17.6/35 Revenue — · PAT — · OPM change -5 pp 26% evidence | 8.8/25 ROCE 16.1% · OPM 9% 95% evidence | 11.5/20 P/E 21.6× · PEG — 15% evidence | 5.4/20 RS sector -9.6% · RS bench -18% · 1Y -35.1%1 of 10 weeks ahead 70% evidence |
| Exact sum: 17.6 + 8.8 + 11.5 + 5.4 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Marsons Ltd's share price today?
Marsons Ltd trades at ₹110, −43.3% over the past year. The company is valued at ₹1,894 Cr. The stock sits at 0% of its 52-week range of ₹110–₹184, −22.6% versus its 200-day average. On the tape, the price is in a downtrend, 41 weeks in. — as of 31 July 2026.
What were Marsons Ltd's latest quarterly results?
Marsons Ltd reported revenue of ₹93.0 Cr and net profit of ₹23.0 Cr for the Mar 26 quarter. Revenue rose 66.1% and profit rose 155.6% year on year. Earnings per share were ₹1.31. The operating margin was 21.0%, 3.0 pp higher than a year earlier. — as of 31 July 2026.
What is Marsons Ltd's revenue?
Marsons Ltd reported revenue of ₹93.0 Cr in the Mar 26 quarter, +66.1% year on year. For the full FY26 fiscal year, revenue was ₹245 Cr (+45.8%). Over the last 10 years revenue compounded at 9.1% a year. — as of 31 July 2026.
What is Marsons Ltd's profit?
Marsons Ltd earned ₹23.0 Cr of net profit in the Mar 26 quarter, +155.6% year on year. Full-year FY26 profit was ₹46.0 Cr. The operating margin ran 21.0% in the latest quarter. — as of 31 July 2026.
What is Marsons Ltd's market cap?
Marsons Ltd's market capitalisation is ₹1,894 Cr at a share price of ₹110. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Marsons Ltd's P/E ratio?
Marsons Ltd trades at a P/E of 40.9×, at the 31st percentile of its own 10-year range, against a long-run median of 71.6×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Marsons Ltd pay a dividend?
Yes — Marsons Ltd's dividend payout was 2% of profit in FY26, and it recorded a payout in 3 of its last 15 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Marsons Ltd overvalued?
On its own history, Marsons Ltd looks cheap against its own history: its P/E of 40.9× has been cheaper only 31% of the time in 10 years (long-run median 71.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Marsons Ltd growing?
Yes — Marsons Ltd is growing: latest-quarter revenue +66.1% year on year, profit +155.6%, and the margin +3.0 pp at 21.0%. The 10-year compound rates are 9.1% (revenue) and 27.7% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Marsons Ltd performing?
Marsons Ltd is in a downtrend, 41 weeks in. Its latest quarter's revenue rose 66.1% and profit rose 155.6% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 15 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Marsons Ltd in?
Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +2579.2% at its peak to +45.6% but is still expanding, ROCE holding at 25.0%. The read comes from the last 12 quarters of growth (revenue growth +45.6% latest, profit growth +70.4% latest, eps growth +66.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Marsons Ltd in an uptrend?
No — the price is in a downtrend (week 41 of stage 4), trading −22.6% versus its 200-day average and at 0% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Marsons Ltd beating the market?
Not lately — on a trailing-13-week view Marsons Ltd is currently behind the NIFTY 500 (15 weeks and counting; last ahead the week of 2026-05-29), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +845% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Marsons Ltd's share price go up?
This page publishes no price forecast for Marsons Ltd. What it measures instead: the share price is ₹110, the price is in a downtrend 41 weeks in. Its P/E of 40.9× sits at the 31st percentile of its own 10-year range. Direction is not something this site claims to know. — as of 31 July 2026.
Who owns Marsons Ltd?
Promoters hold 53.6% of Marsons Ltd, foreign institutions 0.1%, domestic institutions 0.2% and the public 46.0% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Marsons Ltd have too much debt?
No — Marsons Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill 42×. FY26 borrowings were ₹1.0 Cr against equity of ₹217 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Marsons Ltd's capex?
Marsons Ltd spent ₹79.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹77.0 Cr, with ₹25.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Marsons Ltd's cash flow?
Marsons Ltd generated ₹2.0 Cr of operating cash flow in FY26 and ₹−75.0 Cr of free cash flow after ₹77.0 Cr of capital spending. Reported profit that year was ₹46.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Marsons Ltd's profit real cash?
Not fully — over the last 3 fiscal years, −49% of Marsons Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹2.0 Cr against reported profit of ₹46.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Marsons Ltd in its business cycle?
Marsons Ltd's FY26 operating margin was 17.0%, against a 14-year band of −5,506.0%–23.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 21.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Marsons Ltd story?
The sharpest disagreement: profits are rising, but only −49% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Marsons Ltd a stock worth studying right now?
This is not investment advice. The machine read: Marsons Ltd's earnings have outrun its stock. EPS grew +65.0% in a year against a −43.3% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.